142 related articles for article (PubMed ID: 36243001)
21. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
[TBL] [Abstract][Full Text] [Related]
22. Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways.
Kongpetch S; Jusakul A; Ong CK; Lim WK; Rozen SG; Tan P; Teh BT
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):233-44. PubMed ID: 25966424
[TBL] [Abstract][Full Text] [Related]
23. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
[TBL] [Abstract][Full Text] [Related]
24. Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications.
Amadeo E; Rossari F; Vitiello F; Burgio V; Persano M; Cascinu S; Casadei-Gardini A; Rimini M
Expert Rev Clin Pharmacol; 2023; 16(7):631-642. PubMed ID: 37387533
[TBL] [Abstract][Full Text] [Related]
25. Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma.
Yang SZ; Wang AQ; Du J; Wang JT; Yu WW; Liu Q; Wu YF; Chen SG
World J Gastroenterol; 2016 Jul; 22(25):5814-21. PubMed ID: 27433094
[TBL] [Abstract][Full Text] [Related]
26. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
[TBL] [Abstract][Full Text] [Related]
27. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
King G; Javle M
Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
[TBL] [Abstract][Full Text] [Related]
28. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
Farazi PA; Zeisberg M; Glickman J; Zhang Y; Kalluri R; DePinho RA
Cancer Res; 2006 Jul; 66(13):6622-7. PubMed ID: 16818635
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic regulation in the carcinogenesis of cholangiocarcinoma.
Chiang NJ; Shan YS; Hung WC; Chen LT
Int J Biochem Cell Biol; 2015 Oct; 67():110-4. PubMed ID: 26100596
[TBL] [Abstract][Full Text] [Related]
30. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract][Full Text] [Related]
31. Ivosidenib Boosts OS in Cholangiocarcinoma.
Cancer Discov; 2021 Dec; 11(12):2953-2954. PubMed ID: 34635569
[TBL] [Abstract][Full Text] [Related]
32. Regulators of apoptosis in cholangiocarcinoma.
Jhala NC; Vickers SM; Argani P; McDonald JM
Arch Pathol Lab Med; 2005 Apr; 129(4):481-6. PubMed ID: 15794670
[TBL] [Abstract][Full Text] [Related]
33. Quercetin Inhibits Intrahepatic Cholangiocarcinoma by Inducing Ferroptosis and Inhibiting Invasion via the NF-[Formula: see text]B Pathway.
Song Y; Zhang Z; Chai Q; Zheng H; Qi Y; Xia G; Yu Z; Yang R; Huang J; Li Y; Peng C; Jiang B; Liu S
Am J Chin Med; 2023; 51(3):701-721. PubMed ID: 36823098
[TBL] [Abstract][Full Text] [Related]
34. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
Zhu AX; Borger DR; Kim Y; Cosgrove D; Ejaz A; Alexandrescu S; Groeschl RT; Deshpande V; Lindberg JM; Ferrone C; Sempoux C; Yau T; Poon R; Popescu I; Bauer TW; Gamblin TC; Gigot JF; Anders RA; Pawlik TM
Ann Surg Oncol; 2014 Nov; 21(12):3827-34. PubMed ID: 24889489
[TBL] [Abstract][Full Text] [Related]
35. Delivery of miR-200c Mimic with Poly(amido amine) CXCR4 Antagonists for Combined Inhibition of Cholangiocarcinoma Cell Invasiveness.
Xie Y; Wehrkamp CJ; Li J; Wang Y; Wang Y; Mott JL; Oupický D
Mol Pharm; 2016 Mar; 13(3):1073-80. PubMed ID: 26855082
[TBL] [Abstract][Full Text] [Related]
36. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.
Gao Q; Zhao YJ; Wang XY; Guo WJ; Gao S; Wei L; Shi JY; Shi GM; Wang ZC; Zhang YN; Shi YH; Ding J; Ding ZB; Ke AW; Dai Z; Wu FZ; Wang H; Qiu ZP; Chen ZA; Zhang ZF; Qiu SJ; Zhou J; He XH; Fan J
Gastroenterology; 2014 May; 146(5):1397-407. PubMed ID: 24503127
[TBL] [Abstract][Full Text] [Related]
37. Target molecular treatment markers in Intrahepatic Cholangiocarcinoma based on Chinese population.
Pu X; Zhu L; Li F; Zheng J; Wu H; Fu Y; Chen J; Qi L
Pathol Res Pract; 2020 Sep; 216(9):153116. PubMed ID: 32825971
[TBL] [Abstract][Full Text] [Related]
38. ZHX1 Promotes the Proliferation, Migration and Invasion of Cholangiocarcinoma Cells.
Kwon RJ; Han ME; Kim JY; Liu L; Kim YH; Jung JS; Oh SO
PLoS One; 2016; 11(11):e0165516. PubMed ID: 27835650
[TBL] [Abstract][Full Text] [Related]
39. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.
Sia D; Tovar V; Moeini A; Llovet JM
Oncogene; 2013 Oct; 32(41):4861-70. PubMed ID: 23318457
[TBL] [Abstract][Full Text] [Related]
40. Role of epigenetic alterations in cholangiocarcinoma.
Tischoff I; Wittekind C; Tannapfel A
J Hepatobiliary Pancreat Surg; 2006; 13(4):274-9. PubMed ID: 16858537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
